Track your progress with something simple, like noting how many reps you complete or how heavy you lift
[1] Tirzepatide (Mounjaro, Zepbound) has a half-life of approximately 5 days, with elimination taking about 4-5 weeks after the last dose
visits during heat wave02:17 | July 7, 2026 Health Matters: European heatwave continues to devastate France02:15 | June 29, 2026 Health Matters: European heat wave causing hospital machines to fail02:08 | June 25, 2026 More than 1,000 confirmed cases of Ebola in DRC01:21 | June 22, 2026 Health Matters: Experts call for more AI safeguards in online safety bill02:20 | June 22, 2026 Health Matters: Judge dismisses bid to stall closure of Alberta supervised drug sites01:42 | June 17, 2026 Health Matters: Britain to ban social media for kids under 1602:31 | June 15, 2026 Health Matters: Quebec bans energy drinks for people under 1602:15 | June 12, 2026 Health Matters: World Cup visitors warned about drug supply02:44 | June 10, 2026 Health Matters: Canadian who tested positive for hantavirus has recovered02:33 | June 9, 2026 Health Matters: Confirmed Ebola cases continue to rise in Congo outbreak02:40 | June 8, 2026 Health Matters: Ottawa tables first national strategy on eye care02:28 | June 5, 2026 Health Matters: Support for MAID law remains high in Canada, Angus Reid survey says02:30 | June 1, 2026 Health Matters: Head of WHO arrives in Congo amid Ebola outbreak01:59 | May 29, 2026 Mental health conditions on the rise in Canada, CIHI report says01:53 | May 28, 2026 Health Matters: Mental health conditions on the rise in Canada, CIHI report02:02 | May 28, 2026 Health matters: Federal health minister announces launch of new drug analysis centre02:24 | May 27, 2026 DRC Treatment hospital attacked during Ebola outbreak02:26 | May 25, 2026 Health Matters: Lyme disease on the rise in Montreal02:15 | May 22, 2026 Private companies looking to fill care gap for menopausal, perimenopausal women01:53 | May 20, 2026 Health Matters: Global risk of Ebola outbreak spreading remains low, WHO says02:16 | May 20, 2026 Health Matters: Estimated 3M Canadian currently taking GLP-1 drugs, Leger survey finds Description March 3, 2026 Nearly three million Canadian adults are currently taking GLP-1 drugs like Ozempic or Wegovy according to new data
"When you stop these low doses of these drugs, we don't know what's going to happen." On average, people will lose significantly less weight than they would with the maximum dose of a brand name version of the drug, McGowan agrees
Federal regulators state that manufacturers are not permitted to decide whether an event must be reported
The results suggest that sweet al.monds may be beneficial in improving sleep quality [181]
